Skip to main content

Table 6 Association between immunosuppressive therapy and renal composite outcome (after PSM)

From: Effects of immunosuppressive therapy on renal prognosis in primary membranous nephropathy

 

Crude model

 

Adjusted model*

HR

p value

 

HR

p value

Composite outcome

0.65

0.0047

 

0.70

0.0241

Low risk1

1.19

0.5873

 

1.12

0.7537

Moderate risk

0.5

0.0174

 

0.47

0.0196

High risk

0.53

0.0043

 

0.61

0.0374

A > 30% decline of eGFR

0.65

0.0055

 

0.71

0.0305

Low risk1

1.21

0.5499

 

1.16

0.6917

Moderate risk

0.49

0.0169

 

0.47

0.0181

High risk

0.53

0.004

 

0.6

0.0304

A > 50% decline of eGFR

0.71

0.0405

 

0.78

0.1474

Low risk1

1.36

0.3697

 

1.4

0.4364

Moderate risk

0.57

0.0939

 

0.61

0.1626

High risk

0.54

0.0123

 

0.6

0.0561

ESRD

0.35

0.1224

 

0.18

0.0473

High risk2

0.09

0.0271

 

0.00

< 0.0001

Hemodialysis

0.31

0.0793

 

0.16

0.0408

High risk2

0.09

0.0271

 

0.00

< 0.0001

  1. Abbreviations: ESRD, end stage renal disease
  2. *Adjust for age, gender, BMI, blood pressure, diabetes mellitus, hypertension, nephrotic syndrome, albumin, total cholesterol, eGFR-EPI, 24-hour protein quantification and comedications
  3. 1Adjust for above factors except for nephrotic syndrome. None of the PMN patients at low risk had combined nephrotic syndrome
  4. 2No more than two patients progressed to ESRD or hemodialysis in low- and moderate-risk patients respectively, so only cumulative incidence of high-risk patients was analyzed
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us